more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research Published on August 26,2019

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ABBVNegative Net Change

AbbVie (ABBV) Down 1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on August 25,2019

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ABBVNegative Net Change

Amgen Presents Positive Data From Rituxan Biosimilar Study

by Zacks Equity Research Published on August 23,2019

Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.

biotechs

Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit

by Kinjel Shah Published on August 23,2019

FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.

pharmaceuticals

Synlogic Discontinues Development of SYNB1020, Stock Down

by Zacks Equity Research Published on August 21,2019

Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

Bayer Sells Animal Health Division to Elanco: Now What?

by Mitchell Moore Published on August 20,2019

On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

Here's Why Allergan is Outperforming Its Industry Of Late

by Zacks Equity Research Published on August 20,2019

Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

pharmaceuticals

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

by Zacks Equity Research Published on August 19,2019

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

pharmaceuticals

Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe

by Zacks Equity Research Published on August 16,2019

The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.

biotechs

Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

by Zacks Equity Research Published on August 14,2019

Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

pharmaceuticals

Should Value Investors Consider AbbVie (ABBV) Stock Now?

by Zacks Equity Research Published on August 13,2019

Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

ABBVNegative Net Change

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

by Kinjel Shah Published on August 09,2019

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

pharmaceuticals

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research Published on August 09,2019

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ABBVNegative Net Change

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

by Zacks Equity Research Published on August 06,2019

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

pharmaceuticals

Top Research Reports: Chevron, AbbVie, Phillips 66 & More

by Kalyan Nandy Published on August 06,2019

Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), AbbVie (ABBV) and Phillips 66 (PSX).

Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research Published on August 05,2019

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research Published on August 05,2019

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

by Kinjel Shah Published on August 02,2019

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

pharmaceuticals

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

by Zacks Equity Research Published on July 30,2019

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

pharmaceuticals

Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y

by Zacks Equity Research Published on July 30,2019

Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.

pharmaceuticals